Atrial Septal Defect 5 (ASD5) Cell Models for Research

Atrial Septal Defect 5 (ASD5) is a congenital heart defect characterized by an abnormal opening in the atrial septum. According to the World Health Organization (WHO), congenital heart defects affect approximately 1 in 100 newborns worldwide, with atrial septal defects accounting for about 10-15% of these cases. The global incidence of ASD is estimated at 1.6 per 1,000 live births. While surgical and catheter-based interventions have improved outcomes, untreated ASD can lead to complications such as pulmonary hypertension, heart failure, and arrhythmias. The 5-year survival for repaired ASD is excellent, but long-term morbidity remains a concern. ASD5 specifically is a genetic subtype linked to mutations in the NKX2-5 gene, which is crucial for cardiac development. Research into ASD5 is vital for understanding the molecular mechanisms underlying septal formation and for developing targeted therapies.

ASD5 serves as an ideal model for studying cardiac development and congenital heart disease. The genetic basis is well-defined, with NKX2-5 mutations being a common cause. This allows for precise genetic manipulation in cell models to dissect molecular pathways. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Human Cell Atlas, provide expression data for cardiac tissues. Open questions include the role of modifier genes, the impact of specific NKX2-5 mutations on protein function, and the development of personalized therapies. Gene-edited cell models enable functional studies of these mutations in a controlled environment.

While ASD5 is not a cancer, the molecular pathways involved in cardiac development are critical. The major pathways include:

• • NKX2-5 signaling: NKX2-5 is a transcription factor that regulates the expression of genes involved in cardiac morphogenesis. Mutations lead to haploinsufficiency or dominant-negative effects, disrupting septal formation.
• • TBX5 pathway: TBX5 interacts with NKX2-5 to synergistically activate cardiac gene expression. Mutations in TBX5 cause Holt-Oram syndrome, which includes ASD.
• • GATA4 pathway: GATA4 is another transcription factor that cooperates with NKX2-5. Mutations in GATA4 are associated with ASD.
• • Notch signaling: Notch pathway components are involved in the development of the atrial septum. Dysregulation can lead to septal defects.

Data from ClinVar and COSMIC.

The key signaling networks deregulated in ASD5 include:

• • Cardiac transcription factor network: NKX2-5, TBX5, GATA4, and others form a regulatory network that controls cardiac gene expression. Mutations disrupt this network.
• • BMP signaling: Bone morphogenetic proteins (BMPs) are involved in septal formation. Altered BMP signaling can contribute to ASD.
• • Wnt signaling: Wnt/β-catenin pathway plays a role in cardiac development. Dysregulation may affect septation.
• • Notch signaling: Notch receptors and ligands are expressed in the developing heart. Mutations in Notch pathway genes have been linked to ASD.

Organoids derived from iPSCs can model cardiac development and are useful for studying ASD5. They recapitulate early heart development and allow for drug testing.

• • Genetically engineered mouse models (GEMMs): Knockout of Nkx2-5 in mice leads to embryonic lethality, but heterozygous mice show ASD. Conditional knockouts allow for tissue-specific studies.
• • Zebrafish models: Zebrafish with nkx2.5 mutations exhibit cardiac defects, providing a high-throughput screening platform.
• • Rat models: CRISPR-generated rat models with Nkx2-5 mutations are used for studying ASD.
• • Patient-derived xenografts (PDX) are not applicable for ASD as it is not a cancer.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific ASD5 mutations. For example, a NKX2-5 knockout cell line can be generated in iPSC-derived cardiomyocytes to study the loss-of-function effects. Alternatively, a knock-in line carrying a specific missense mutation (e.g., R25C) can be created to model a patient-specific variant. These models are sequence-verified and commercially available, accelerating research by providing consistent and reproducible tools. They are essential for functional studies and drug screening.

Gene-edited cell models are used to validate the functional impact of ASD5-associated genes. For instance, knocking out NKX2-5 in iPSC-derived cardiomyocytes can reveal changes in gene expression and electrophysiological properties. Knock-in of specific mutations allows for studying the effect of the mutation on protein function. These models help identify downstream targets and pathways.

Isogenic pairs (wild-type vs. mutant) are used in high-throughput drug screening to identify compounds that rescue the mutant phenotype. For example, screening for drugs that restore NKX2-5 transcriptional activity in mutant cells could lead to therapeutic candidates. Additionally, gene-edited cells can be used to study drug resistance mechanisms in the context of cardiac toxicity.

CRISPR-based synthetic lethality screens can identify genes that are essential in ASD5-mutant cells but not in wild-type cells. These genes could serve as biomarkers or therapeutic targets. For example, a screen in NKX2-5 knockout cells might reveal a dependency on a specific signaling pathway that can be targeted.